Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clarithromycin clinical pharmacokinetics

F Fraschini1, F Scaglione, G Demartini

  • 1Department of Pharmacology, University of Milan, Italy.

Clinical Pharmacokinetics
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Host factors and history of SARS-CoV-2 infection impact the reactogenicity of BNT162b2 mRNA vaccine: results from a cross-sectional survey on 7,014 workers in healthcare.

European review for medical and pharmacological sciences·2022
Same author

Sick leave request following anti-COVID-19 vaccine administration is low among healthcare workers: results from a retrospective cross-sectional monocentric study.

European review for medical and pharmacological sciences·2021
Same author

Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management.

ESMO open·2021
Same author

OM-85 in the prevention of respiratory infections: State-of-the-art and future perspectives in clinical practice.

Journal of biological regulators and homeostatic agents·2021
Same author

Strategies to tackle RAS-mutated metastatic colorectal cancer.

ESMO open·2021
Same author

Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen.

Journal of global antimicrobial resistance·2017
Same journal

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.

Clinical pharmacokinetics·2026
Same journal

Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics.

Clinical pharmacokinetics·2026
Same journal

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same journal

Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing.

Clinical pharmacokinetics·2026
Same journal

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Clinical pharmacokinetics·2026
Same journal

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.

Clinical pharmacokinetics·2026
See all related articles

Clarithromycin, a macrolide antibiotic, offers improved pharmacokinetics over erythromycin, allowing twice-daily dosing. Its active metabolite and good tissue distribution make it a viable option for community-acquired infections.

Area of Science:

  • Pharmacology
  • Microbiology
  • Drug Metabolism

Background:

  • Clarithromycin is a semisynthetic macrolide antibiotic.
  • It is structurally related to erythromycin but possesses a more favorable pharmacokinetic profile.
  • This profile allows for less frequent administration, potentially improving patient compliance.

Purpose of the Study:

  • To evaluate the pharmacokinetic properties of clarithromycin.
  • To compare its absorption, distribution, metabolism, and excretion (ADME) with erythromycin.
  • To assess its suitability as an alternative macrolide for treating community-acquired infections.

Main Methods:

  • Pharmacokinetic analysis of oral clarithromycin administration.
  • Measurement of serum and tissue concentrations of clarithromycin and its active metabolite (14-hydroxy derivative).

Related Experiment Videos

  • Assessment of metabolic pathways, including N-demethylation and hydroxylation, and their impact on pharmacokinetics.

    • Main Results:

    • Clarithromycin is well absorbed with a bioavailability of approximately 55%, reduced by first-pass metabolism.
    • It rapidly forms a microbiologically active 14-hydroxy metabolite.
    • Steady-state serum concentrations are achieved within 5 doses, with peak concentrations appearing within 2 hours post-dose.
    • The drug distributes well into tissues, achieving higher concentrations than in blood.
    • Food intake does not significantly affect its pharmacokinetics.
    • Metabolism involves saturable oxidative N-demethylation and hydroxylation, leading to nonlinear pharmacokinetics.
    • Renal impairment and age increase drug exposure (AUC, Cmax, t1/2).
    • Mild hepatic impairment has minimal impact on clarithromycin pharmacokinetics.

    Conclusions:

    • Clarithromycin exhibits favorable pharmacokinetic properties, including good absorption, tissue penetration, and a microbiologically active metabolite.
    • Its predictable pharmacokinetic profile and efficacy support its use as an alternative macrolide for community-acquired infections.
    • Dosage adjustments may be necessary in patients with renal impairment and the elderly.